This week in Other Barks & Bites: the Supreme Court of Japan rules that students taking lessons at music schools are not subject to copyright fees for in-lesson performances for instructors; the England and Wales Court of Appeal denies Apple’s request to set aside an injunction in its SEP/FRAND case with Optis Cellular; Retired Chief Judge Paul Michel urges the Federal Circuit to issue more en banc decisions to clarify patent law; the Federal Circuit reverses a district court’s preliminary injunction for applying the improper legal standard in determining the plaintiff’s likelihood of success in a design patent suit against Gyroor hoverboards; Elon Musk’s takeover of Twitter begins by firing executives linked to misreported bot accounts; Senators Thom Tillis and Chris Coons ask the U.S. Patent and Trademark Office and the U.S. Copyright Office to collaborate on a national commission on AI; and more.
Patent
- Enablement
- Fee Shifting
- Litigation
- Other Barks & Bites for Friday, March 31: Japan Restricts Chip-Making Exports, Ocado Scores UK High Court Win in Robotic Warehousing Case, and Judge Rejects Fair Use Defense for Internet Archive
- U.S. Government Sides with Teva in Skinny Label SCOTUS Fight
- Industry, NGOs Spar Over Need to Extend TRIPS COVID IP Waiver at ITC Hearing
- Software-Related U.S. Patent Grants in 2022 Remained Steady While Chinese Software Patents Rose 8%
- The Truth Leaks Out: Justices Struggle with the Science, Sanofi Welcomes End to Functional Genus Claims in Amgen Oral Arguments
Recent Posts
- Other Barks & Bites for Friday, March 31: Japan Restricts Chip-Making Exports, Ocado Scores UK High Court Win in Robotic Warehousing Case, and Judge Rejects Fair Use Defense for Internet Archive
- U.S. Government Sides with Teva in Skinny Label SCOTUS Fight
- Industry, NGOs Spar Over Need to Extend TRIPS COVID IP Waiver at ITC Hearing
- Software-Related U.S. Patent Grants in 2022 Remained Steady While Chinese Software Patents Rose 8%
- The Truth Leaks Out: Justices Struggle with the Science, Sanofi Welcomes End to Functional Genus Claims in Amgen Oral Arguments